Skip to main content

Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease.

Publication ,  Journal Article
Koch, RL; Cocanougher, BT; Lim, J-A; Raben, N; Kishnani, PS
Published in: Ann Transl Med
December 24, 2024

Duke Scholars

Published In

Ann Transl Med

DOI

ISSN

2305-5839

Publication Date

December 24, 2024

Volume

12

Issue

6

Start / End Page

123

Location

China

Related Subject Headings

  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Koch, R. L., Cocanougher, B. T., Lim, J.-A., Raben, N., & Kishnani, P. S. (2024). Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease. Ann Transl Med, 12(6), 123. https://doi.org/10.21037/atm-24-135
Koch, Rebecca L., Benjamin T. Cocanougher, Jeong-A Lim, Nina Raben, and Priya S. Kishnani. “Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease.Ann Transl Med 12, no. 6 (December 24, 2024): 123. https://doi.org/10.21037/atm-24-135.
Koch, Rebecca L., et al. “Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease.Ann Transl Med, vol. 12, no. 6, Dec. 2024, p. 123. Pubmed, doi:10.21037/atm-24-135.

Published In

Ann Transl Med

DOI

ISSN

2305-5839

Publication Date

December 24, 2024

Volume

12

Issue

6

Start / End Page

123

Location

China

Related Subject Headings

  • 42 Health sciences
  • 32 Biomedical and clinical sciences